LY334370 is primarily investigated for its potential therapeutic applications in the treatment of neurological and psychiatric disorders. It acts as a selective agonist for the 5-HT1F receptor, which is involved in the regulation of serotonin signaling in the brain. This makes it a promising candidate for the management of migraines, as targeting the 5-HT1F receptor can help alleviate migraine symptoms without the cardiovascular side effects associated with other serotonin receptor agonists. Additionally, its role in modulating serotonin pathways suggests potential utility in addressing conditions such as anxiety and depression, where serotonin dysregulation plays a critical role. Research is ongoing to further explore its efficacy and safety in these clinical applications.